Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have been given an average rating of "Moderate Buy" by the fifteen research firms that are presently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $158.38.

A number of brokerages have recently commented on SRPT. Barclays upped their price target on Sarepta Therapeutics from $141.00 to $185.00 and gave the company an "overweight" rating in a research report on Thursday, February 29th. TheStreet raised Sarepta Therapeutics from a "d" rating to a "c-" rating in a research report on Monday, March 4th. Mizuho upped their price target on Sarepta Therapeutics from $130.00 to $145.00 and gave the company a "buy" rating in a research report on Wednesday, February 14th. Wedbush reaffirmed an "outperform" rating and set a $224.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Finally, Evercore ISI upped their price target on Sarepta Therapeutics from $108.00 to $138.00 and gave the company an "in-line" rating in a research report on Tuesday, February 20th.

Sarepta Therapeutics Stock Performance

SRPT stock traded down $1.06 during midday trading on Monday, hitting $128.40. The company's stock had a trading volume of 858,170 shares, compared to its average volume of 1,075,642. The stock's 50-day moving average price is $126.31 and its 200 day moving average price is $109.90. The company has a quick ratio of 3.45, a current ratio of 3.95 and a debt-to-equity ratio of 1.32. Sarepta Therapeutics has a 1 year low of $55.25 and a 1 year high of $159.89.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.50. Sarepta Therapeutics had a negative return on equity of 18.97% and a negative net margin of 43.11%. The business had revenue of $396.80 million for the quarter, compared to analysts' expectations of $387.18 million. During the same quarter in the previous year, the firm earned ($1.24) earnings per share. The business's revenue was up 53.6% on a year-over-year basis. As a group, research analysts predict that Sarepta Therapeutics will post 1.94 earnings per share for the current year.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 761 shares of the company's stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $122.93, for a total value of $93,549.73. Following the transaction, the director now directly owns 7,516 shares in the company, valued at approximately $923,941.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Kathryn Jean Boor sold 761 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $122.93, for a total transaction of $93,549.73. Following the transaction, the director now directly owns 7,516 shares in the company, valued at approximately $923,941.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Bilal Arif sold 2,000 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.84, for a total value of $257,680.00. Following the transaction, the insider now owns 26,836 shares in the company, valued at $3,457,550.24. The disclosure for this sale can be found here. Insiders have sold 22,096 shares of company stock worth $2,739,419 in the last ninety days. 7.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Sarepta Therapeutics by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 8,572,944 shares of the biotechnology company's stock valued at $1,039,212,000 after purchasing an additional 41,465 shares during the last quarter. Picton Mahoney Asset Management purchased a new stake in Sarepta Therapeutics during the 3rd quarter valued at about $2,576,000. Capula Management Ltd purchased a new stake in Sarepta Therapeutics during the 3rd quarter valued at about $1,409,000. Victory Capital Management Inc. boosted its holdings in Sarepta Therapeutics by 17.3% during the 3rd quarter. Victory Capital Management Inc. now owns 87,386 shares of the biotechnology company's stock valued at $10,593,000 after acquiring an additional 12,894 shares during the period. Finally, Handelsinvest Investeringsforvaltning purchased a new stake in Sarepta Therapeutics during the 4th quarter valued at about $302,000. 86.68% of the stock is currently owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.